S100 AND COGNITIVE IMPAIRMENT AFTER MILD TRAUMATIC BRAIN INJURY
Catharina Nygren de Boussard A1, Anders Lundin A1, Daniel Karlstedt A1, Gunnar Edman A2, Aniko Bartfai A3, Jörgen Borg A4
A1 Department of Rehabilitation Medicine
A2 R&D Unit, Department of Psychiatry, Karolinska Institutet Danderyds Hospital Stockholm
A3 Department of Rehabilitation Medicine, Karolinska Institutet Huddinge University Hospital Stockholm
A4 Department of Neuroscience, Rehabilitation Medicine Uppsala University Sweden
Objective: The aim of this study was to explore the relationship between the proteins S100B and S100A1B and symptoms and signs of cognitive impairment for 3 months after mild traumatic brain injury (MTBI). Methods: Serum concentrations of S100A1B and S100B were examined in a prospective cohort study of patients with MTBI and a Glasgow Coma Scale score of 14 or 15. Cognitive performance was assessed by repeated computerized neuropsychological testing and an extended neuropsychological test. Symptoms were assessed using the Rivermead Post-Concussion Symptoms Questionnaire. Results: Concentrations of S100B and S100A1B were above cut-off in 31% and 48% respectively. Eight percent of the patients had signs of cognitive impairment according to the computerized neuropsychological tests and 30% according to the extended test. Symptoms of cognitive impairment were reported by 44% of the patients on the first day post-injury and by 26% at 3 months. No significant associations between S100B or S100A1B concentrations and symptoms or signs of cognitive impairment were found. Conclusion: Abnormal S100 serum concentrations and symptoms or signs of cognitive impairment were not significantly associated in patients with MTBI and a Glasgow Coma Scale score of 14 or 15.